**Supplemental Digital Content 2.** Summary of patients with NAFLD

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Gender | Age (years) | Time since diagnosis (mos) | Diagnosis | Disease location | Steroids (current vs last 6 mo vs neither) | Current medication | Family history IBD | Family history liver disease | ALT level (IU/L) | Weight status,  BMI (kg/m2) (percentile for age) | BMI change over prior 6 mo  BMI | Bowel surgery | PDFF (%) |
| 1 | Male | 13.6 | 1 | Indeterminate colitis | Recto-sigmoid | Current | mesalamine | Positive | Negative | 12 | Normal  20.1  (66) | Increased  +0.6 | No | 5.3 |
| 2 | Male | 18.9 | 77 | Crohn’s | Ileum, ascending colon | Neither | infliximab | Positive | Negative | 31 | Obese  35.7  (>99) | Decreased  -0.2 | Yes | 9.9 |
| 3 | Female | 15.3 | 29 | Crohn’s | Ileum, ascending, transverse, descending, recto-sigmoid colon | Last 6mo | infliximab | Positive | Negative | 22 | Normal  22.7  (76) | No change  0.0 | No | 5.6 |
| 4 | Male | 11.8 | 110 | Crohn’s | Ileum, ascending, transverse, descending, recto-sigmoid colon | Neither | infliximab | Negative | Negative | 10 | Overweight  21.4  (88) | Increased  +0.3 | No | 5.3 |
| 5 | Male | 13.3 | 1 | Crohn’s | Ileum | Current | adalimumab | Negative | Negative | 5 | Normal  19.1  (56) | Decreased  -0.4 | No | 5.2 |